chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vaccine was not diluted prior to administering to student.  Student was give 0.2ml of undiluted vaccine.
Child fainted within seconds of final vaccine.  Cold towel to face. Child regained consciousness, then fainted again and jerked twice before regaining consciousness again. Placed child to lying position with legs elevated, administered O2 @ 6L per mask. EMS called and  transported child to ER.
This is a spontaneous report received from a contactable Nurse via Pfizer sales representative. A patient of unspecified age ethnicity and gender received TRUMENBA via an unspecified route of administration at single dose on an unspecified date for immunisation. The patient medical history and concomitant medications were not reported. The patient experienced arm soreness on an unspecified date with outcome of unknown.
Patient began to feel light headed after vaccine administration and then began to slur speech and show diminished cognitive function. Patient the stopped responding and breathing continued to diminish with lips starting to change color within 5 minutes. 911 was called. Patient was given Epinephrine 0.3 mg in left upper leg. Patient started to respond and regained consciousness. Patient continued to talk and EMT showed up 3-5 minutes later. Blood pressure was taken by them and was reported as low to patient. Was told she needed to go to hospital. They wanted to drive themselves. Patient took a bendaryl that was given to her by husband. Patient left for hospital per husband.  Patient had reported fasting for the entire day. Water was given with a glucose tablet.
12/30 vaccine. Within minutes, HA. 'felt weird'. Dizziness and nausea within 30 minutes.  Tx to the ED. provided zofran.  Symptoms for about 3 days.
This case was reported by a lawyer and described the occurrence of joint pain in a male subject of unspecified age who was vaccinated with lyme disease vaccine recombinant (Lymerix) for prophylaxis. A physician or other health care professional has not verified this report. On an unspecified date the subject received unspecified dose of Lymerix unknown. At an unspecified time after vaccination with Lymerix, the subject experienced pain in his joints, fatigue possible autoimmune disease, decreased activities of daily life, possible neurological injuries, respiratory problems, heart problems and muscle weakness. The subject died. The cause of death was not reported. It was unknown whether an autopsy was performed. This information was received via a statement of injuries.
administered Kinrix to an 11 year old; This case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 11-year-old male patient who received DTPa-IPV (Kinrix) (batch number 3DZ45, expiry date 15th January 2022) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   In February 2021, the patient received Kinrix and Kinrix Pre-Filled Syringe Device. In February 2021, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 3-Aug-2022 Reporter's comment: The licensed practical nurse called in to inquired how to proceed or the patient need to be vaccinated with a Boostrix. No additional details were provided. The reporter did not consent to follow-up. The reporter reported that the patient received a dose of Kinrix at inappropriate age, which led to inappropriate age at vaccine administration.
Shortly after the vaccine, my left arm became very painful to the point where I could not sleep on my left side, had trouble reaching or stretching, and a general muscle ache centering around the injection site and around and down my upper arm. Almost 60 days later it is getting steadily worse.
Information has been received from a nurse referring to multiple unspecified patients of unknown age and gender. information about concurrent conditions, medical history and concomitant medication was not provided. On unknown dates the patients were vaccinated with a dose of MMR II (lot# L012480, expiration date 10-APR-2017, dose, dose# and route unknown) which were improperly stored. Temperature and time frame was 11 degree for 35.5 hours as well as 0 degree for 241 hours. No adverse effect reported. This is one of several reports received from the same source. Additional information has been requested.
Tinnitus after first three shot / Chirping in my head; This spontaneous case was reported by a patient and describes the occurrence of TINNITUS (Tinnitus after first three shot / Chirping in my head) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039F4A, 001B21A and 031L20A) for COVID-19 prophylaxis.     It was reported that patient had never diagnosed or tested positive with COVID-19. It was reported that patient did not had any acute illness at the time of vaccination and up to one month before. Patient had not experienced any similar event in the past.  Concurrent medical conditions included Blood cholesterol abnormal and Insomnia. Concomitant products included ATORVASTATIN from 2020 to an unknown date for Blood cholesterol abnormal, ZOLPIDEM TARTRATE (AMBIEN) from 2012 to an unknown date for Insomnia.   On 12-Feb-2021 at 12:10 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Feb-2021, the patient experienced TINNITUS (Tinnitus after first three shot / Chirping in my head). At the time of the report, TINNITUS (Tinnitus after first three shot / Chirping in my head) had not resolved.            Patient stated that if patient was not concentrating on something or distracted patient used to notice the noise. Patient stated that noises started after the vaccinations. Patient had ordered bone conducting headphones to see whether they could help as people claimed they helped in some cases and was a smooth try. Patient had multiple episodes of tinnitus which occurred on 12-Feb-2021, 12-Mar-2021 and 09-Nov-2021. Route and body site for all doses were reported. The event did not caused patient to seek medical case.  Treatment medications were not reported.   This case was linked to MOD-2022-642006 (Patient Link).
Sciatic nerve problems; Nerve damage in the injection arm; Mono; Herpes zoster reactivation; Herpes simplex reactivation; Immediately after receiving the vaccine I noticed a difference (IQ)/ As soon as I got the ZOSTAVAX vaccine my IQ shot back up to 159; This spontaneous report has been received from a consumer referring to herself as an adult female patient of unknown age. The patient's pertinent medical history included history of mono, chicken pox multiple times, and family history of Alzheimer. Patient's concomitant medication included levothyroxine, topiramate, and allergy pills. Patient's drug reactions or allergies included baby aspirin.  On an unknown date in 2018 (also reported as 4 years ago), the patient was vaccinated with zoster vaccine live (ZOSTAVAX) subcutaneous injection, (dose, strength, frequency, site of vaccination, route of administration, expiration date, and lot number were not provided) administered for prophylaxis. On an unknown date, the patient was vaccinated with a COVID-19 vaccine (reported as Johnson and Johnson COVID 19 vaccine), and on December 10th of an unknown year, the patient vas vaccinated with elasomeran (MODERNA COVID-19 VACCINE).  The reporter stated that the zoster vaccine live (ZOSTAVAX), had a benefit she did not expect "I did not know at the time, but the zoster vaccine live (ZOSTAVAX) cured herpes type 1 and type 2". She stated that her intelligent quotient (IQ) was 159 and it tanked at 75 (before vaccine) and no one could figure out the reason; immediately after she received the vaccine, she noticed a difference. It was also reported that as soon as she got the zoster vaccine live (ZOSTAVAX), her IQ shot back up to 159 (unexpected therapeutic benefit). The reporter informed that at the time she received the zoster vaccine live (ZOSTAVAX), she did not realize she had herpes type 1. She also stated that, after she received the Johnson and Johnson COVID-19 vaccine, it reactivated all the viruses she previously suffered from (herpes zoster reactivation and herpes simplex reactivation). Additionally, she reported that after she received one of the COVID 19 vaccines, she experienced nerve damage in the injection arm (vaccination site nerve damage), mono (mononucleosis infectious), and sciatic nerve problems (sciatic nerve neuropathy). The causal relationship between pembrolizumab (KEYTRUDA) and the events were not provided.  The outcome of the events was not provided. The action taking regarding the suspect therapy and the events was not provided.
I had low grade fever for 5 days and after 5 days it went up to 103.0 and I was unable to get it down. I went to the hospital and was admitted. My inflammation markers were higher than a patient with cancer. My markers were around 16 when they should be around 5. I was given potassium, Tylenol, and ibuprofen to get my fever down. I was admitted around noon and had to stay in the hospital for approximately 2 days. I had to follow up with my PCP multiple times and my inflammation markers began to come back down. I still suffer from low energy levels, aches, and elevated inflammation levels. I was unable to eat initially and did not have any energy.
Within 24 hours developed sever arm pain with large, hot red area below injection site, as well as high fever (102 degrees), chills, nausea, malaise, body aches. Most resolved within 48 hours EXCEPT the arm pain and hot red area below injection site which are still present 1 week post injection.
Administered a second Pfizer COVID Bivalent vaccine after patient received one on 9-3-22.
High fever (103.9), headache, diarrhea, nausea, muscle pain, joint pain, sinus pain/pressure, post nasal drip, thick sputum from nose, deep cough, thick sputum from lungs, vision impairment, sore throat, mental fog, extreme exhaustion
Breakthrough case admission after 3 vaccines Moderna 4/22/21 Lot# 030A21A;  Moderna 5/20/21 Lot# 022B21A;  Moderna 12/23/21 Lot# 033H21A
I received the Pfizer booster after having moderna for vaccination #1 and #2.  I began wheezing at the 5 hour post vaccination and then was coughing and feverish and had significant malaise and body aches and eye pain and headaches with vomiting and diarrhea for 3 days.
6/3/07 Generalized malaise, hyponatremia, hypokalemia hemo concentrated, dehydration. 6/4/07 Myalgia, elevated hematocrit. 6/5/07 Elevated RBS, bilateral lower extremity swelling. 6/26/07 Myalgia likely due to combination vaccine, back pain, possibly due to muscle weakness.
Severe backache, mild headache, mild body aches, mild fever - took 4 ibuprofen first day, oxycodone 2nd day - symptoms mostly gone in 36 hrs.
Pt recvd 3 doses of Engerix-B & 3FEB92 found to be a non-seroconverter;
Hives with itching and redness of face. Responded well to Benadryl dose.
received booster dose from a vial stored >30 days in refrigerator; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (received booster dose from a vial stored >30 days in refrigerator) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Jan-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (received booster dose from a vial stored >30 days in refrigerator). On 29-Jan-2022, EXPIRED PRODUCT ADMINISTERED (received booster dose from a vial stored >30 days in refrigerator) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   No treatment information provided.
Pt received pfizer vaccines on 02/28/21 and 03/21/21. ON 11/07 pt presented to the ED with complaints of SOB. Pt required supplemental oxygen. CXR showed COVID pneumonia.   Pt was DNR comfort and expired on 11/12/2021
24 hours after receiving my 2nd Pfizer vaccine, I developed a rash on the back of my left arm. The rash has continued to worsen daily and is now over my entire body. Small bumps and hives flare-up, go away and then reappear in a different area of the body. They are itchy and sometimes burn. I was prescribed Zyrtec at an urgent care facility. I picked up some Calamine lotion and Benadryl cream. Nothing has stopped the outbreak.
This case was reported by a physician via sales rep and described the occurrence of pain in a 55-year-old female patient who received FLUARIX Quadrivalent. On 4th October 2016, the patient received FLUARIX Quadrivalent. On 4th October 2016, less than a day after receiving FLUARIX Quadrivalent, the patient experienced pain, erythema, swelling, injected limb mobility decreased and grip strength decreased. On an unknown date, the outcome of the pain, erythema, swelling, injected limb mobility decreased and grip strength decreased were unknown. It was unknown if the reporter considered the pain, erythema, swelling, injected limb mobility decreased and grip strength decreased to be related to FLUARIX Quadrivalent. Additional details were provided as follows: the patient received FLUARIX Quadrivalent in her left deltoid and the same day developed pain, redness, swelling and limited range of motion in the left arm. The patient stated that she could not hold a jug of milk. On the date of reporting, the patient presented to the physician office and the physician requested an MRI to be taken for further work up. The sales representative did not have patient demographics or vaccine information and unsure if symptoms of redness and swelling had resolved. The pain and limited range of motion had not resolved. The physician would have administered PREVNAR during the visit on the date of reporting, but did not due to patient's complications following FLUARIX vaccination.
Patient woke up on the 28th complaining of severe pain, nausea and vomiting. Was admitted to healthcare facility and kept for observation overnight. On the 29th a CT was done and found bleeding in brain/stroke. Airlifted to healthcare facility where Craniotomy surgery was done.
Swollen and red tonsils, throat, and uvula.  Painful swallowing. Fatigue and headache.  Symptoms started 2/2 7-8 hours after receiving the vaccine and are still persisting 11 days later.
This spontaneous report as received from a licensed vocational nurse concerning a patient of unknown age and gender. Medical history and concurrent conditions were not reported. On an unknown date the patient was vaccinated with a dose of VARIVAX (Merck) (dose, frequency, strength and route were not reported), lot number reported as K003820, expiration date reported as 14-SEP-2015. Co-suspect and concomitant therapies were not reported. The licensed vocational nurse reported that VARIVAX (Merck) were exposed to -14C for 30 minutes and they were administered on an unspecified date to a patient. No adverse effects were reported. These is one (1) of two (2) reports from the same reporter (MARRS 1406USA001137 and 1406USA008023). Additional information has been requested.
Started as a knot and then was swollen, and tender to site.  Noticed swelling in the mirror.  warm but not hot to touch.  Used ice to site.  Is improving.
Fever of 104 F with  rigors,  8/10 pain headache, body aches. Took a gram of acetaminophen, rigor went away temp went down to 102 and slowly dissipated 24 hours later. Body pain and headache gone 48hrs post shot
received first dose on july 2021,  second dose on May 2022; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 14-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMAA636A, expiry date 30th September 2022) for prophylaxis.   Previously administered products included Menveo (received 1st dose on an unknown date in July 2021).   In May 2022, the patient received the 2nd dose of Menveo. In May 2022, unknown after receiving Menveo, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.   Additional Information: GSK receipt date: 19-MAY-2022 Reporter's comment: A nurse reported about a patient who received an early second dose of Menveo.  Additional Supportive Information: The patient received 2nd dose of Menveo, which led to extra dose administered.
I had a very unusual nose bleed one hour after taken the shot. I don?t think it  was a serious event but bc I don?t remember last time I had a bloody nose thought it was worth reporting
Immediate: High fever (100.4), Encephalitis: inconsolable high pitched screaming, lethargy, whimpering, refusal to nurse; She began having neurological symptoms. She started having involontary spasms, she started walking on her toes, stopped responding to her name, started having sensory processing issues and motor planning delays; regressed speech and social skills. She began occuptional and speech therapies and treatment is helping.
INCREDIBLE PAIN IN STERNUM. COULD NOT MOVE. SHORTNESS OF BREATH.  CHEST PAIN SUBSIDED SAME DAY.  SHORTNESS OF BREATH IS ONGOING
A nurse described the occurrence of shortness of breath in a 56 year old female who was vaccinated with hepatitis B vaccine recombinant (Engerix-B) for prophylaxis.  The subject's medical history included vertigo.  The subject experienced no adverse events following previous immunizations.  The subject received no concurrent medications or vaccines.  On 01/13/03, the subject received her first injection of Engerix-B (Lot # ENG5338A6).  On 01/13/03, at 18:00 she began to experience lightheadedness.  At 22:00, she noticed "blotchy" areas on her lower arms.  On 01/14/03 at 02:00, the subject began to experience shortness of breath and "her heart started to race".  These events "progressed through the night."  At 10:00 on 01/14/03, she presented to the local ER.  Her "blotchiness" started to fade.  Unspecified "blood work", chest x-ray and ECG were "fine".  The physician prescribed meclizine hydrochloride (Antivert) 25mg.  The blotchiness, shortness of breath, and racing heart resolved on 01/14/2003; the lightheadedness resolved on approximately 01/15/03.  The reporting nurse considered the events to be possibly related to Engerix-B administration, and the immunization series was discontinued.
I had immense pain under my left arm that woke me up out of my sleep; My lymph nodes are swollen and very painful; My lymph nodes are swollen and very painful; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 09Mar2021 at 16:00 (at the age of 37-years old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. Medical history included COVID-19. Concomitant medication included ethinylestradiol/etonogestrel (NUVARING) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Mar2021 at 00:00, the patient experienced "On the second evening after receiving my first dose, I had immense pain under my left arm that woke me up out of my sleep. My lymph nodes are swollen and very painful". The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events "On the second evening after receiving my first dose, I had immense pain under my left arm that woke me up out of my sleep. My lymph nodes are swollen and very painful" was not recovered at the time of the report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Pt became pale, clammy, collapsed w/assist to floor; appeared to lose consciousness; did not respond to verbal or physical stimuli; feet elevated, BP 110/60-resp nl; pt skin color returned to nl, stated nausea, no vomiting;
Cataract; Pain in arm; This spontaneous case was reported by a physician and describes the occurrence of CATARACT (Cataract) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) injection for Crohn's disease.    The patient's past medical history included Cataract extraction. Concurrent medical conditions included Crohns disease aggravated.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (unknown route) at an unspecified dose. On an unknown date, the patient experienced CATARACT (Cataract) (seriousness criterion medically significant) and PAIN IN EXTREMITY (Pain in arm). At the time of the report, CATARACT (Cataract) and PAIN IN EXTREMITY (Pain in arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not provided. Treatment information was not reported. Company comment: Based on current available information and the temporal association between product use and the start date of the events a causal relationship cannot be excluded. for Pain in Extremity but is unlikely for the event Cataracts.; Sender's Comments: Based on current available information and the temporal association between product use and the start date of the events a causal relationship cannot be excluded. for Pain in Extremity but is unlikely for the event Cataracts.
06/18/02 fever 101.5, rapid breathing at 11pm. Taken to ER for eval.
1 day later after shot, she stated she couldn't walk on one foot. She's had nodes on hands & back of cranium before shot. She never had nodes on foot before shot. Her arthritis flared. Her nodes all enlarged after shot all over body.
This spontaneous report as received from a nurse refers to some patients of unknown ages and genders with no pertinent medical history and drug reactions/allergies. On 11-OCT-2013 the patients was vaccinated with a dose of GARDASIL injection, 0.5 ml, intramuscular (lot# J008423, expiration date 21-JAN-2016). There was no concomitant medication. The nurse was reporting seven patients fainted in the office. The nurse stated some of the seven patients "passed out". No lab diagnostics studies were performed. Treatment was given for the event and the patients were provided with juice, crackers, and were monitored. Action taken with GARDASIL was unknown. All patients left the office fully recovered on 11-OCT-2013. This is one of several reports received from the same source. Additional information has been requested.
5mo p/vax began vomiting 3hr p/vax;no fever reported;pt lethargic;MD prescribed anti-emetic suppository;pt went to sleep prior to giving rx;nothing given;
Difficulty  breathing, - Hx of asthma.    Evaluated by EMS.  O2-99% on room air, HR-68. Client has inhaler in her car and will when discharged.